Outlook Wealth Advisors LLC Has $292,000 Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Outlook Wealth Advisors LLC lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.8% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 541 shares of the company’s stock after purchasing an additional 111 shares during the quarter. Outlook Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $292,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Raymond James & Associates boosted its holdings in shares of IDEXX Laboratories by 1.9% in the first quarter. Raymond James & Associates now owns 74,334 shares of the company’s stock worth $40,135,000 after buying an additional 1,399 shares during the period. Marshall Financial Group LLC boosted its stake in IDEXX Laboratories by 9.8% in the 1st quarter. Marshall Financial Group LLC now owns 1,719 shares of the company’s stock worth $928,000 after purchasing an additional 154 shares during the period. First Trust Direct Indexing L.P. grew its position in IDEXX Laboratories by 22.3% during the 1st quarter. First Trust Direct Indexing L.P. now owns 2,066 shares of the company’s stock worth $1,115,000 after purchasing an additional 377 shares in the last quarter. Advisor Resource Council purchased a new stake in shares of IDEXX Laboratories in the first quarter valued at $210,000. Finally, Kovack Advisors Inc. boosted its position in shares of IDEXX Laboratories by 1.0% in the first quarter. Kovack Advisors Inc. now owns 2,651 shares of the company’s stock worth $1,431,000 after buying an additional 26 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insiders Place Their Bets

In other news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the transaction, the senior vice president now owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the sale, the chief executive officer now directly owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP George Fennell sold 8,198 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the transaction, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at approximately $3,851,815.44. The disclosure for this sale can be found here. Insiders sold 43,524 shares of company stock valued at $24,871,960 over the last 90 days. 2.11% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on IDXX shares. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Piper Sandler cut shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target for the company. in a report on Tuesday, January 30th. Barclays boosted their price objective on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. The Goldman Sachs Group lifted their target price on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Finally, JPMorgan Chase & Co. upped their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $591.50.

IDEXX Laboratories Stock Up 2.1 %

Shares of IDXX traded up $10.06 during mid-day trading on Friday, hitting $499.30. 529,834 shares of the company’s stock were exchanged, compared to its average volume of 416,262. The stock has a market cap of $41.47 billion, a price-to-earnings ratio of 49.58, a P/E/G ratio of 3.77 and a beta of 1.26. The firm has a fifty day moving average of $531.02 and a two-hundred day moving average of $510.75. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.42. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, topping the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The firm had revenue of $901.60 million for the quarter, compared to the consensus estimate of $891.88 million. During the same period in the prior year, the business posted $2.05 earnings per share. The business’s quarterly revenue was up 8.8% on a year-over-year basis. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.